Last week was about who — and what — is qualified. The FDA floated a plan to test generative-AI devices the way residency programs test doctors, and asked industry to weigh in. The same day, the White House named a doctor to run the FDA, and by Thursday the senator who chairs her confirmation committee was questioning whether she's qualified to run anything that large. ARPA-H wrote checks for stroke robots designed to work without a physician's hands. CMS decided a foundation-model AI is worth paying for. And a federal court took up the question of how a market leader is allowed to compete. The bar is being set, by regulators, payers, judges and the Senate, and most of it happened in four days.
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
8 things to watch this week:
1. 🏛️ Trump taps White House aide Heidi Overton to run the FDA
President Trump nominated Dr. Heidi Overton — deputy director of the White House Domestic Policy Council, former America First Policy Institute health chief, and the architect behind the administration’s vaccine-schedule and food-pyramid moves — to fill the commissioner seat vacant since Marty Makary resigned in May. Senate HELP chair Bill Cassidy, whose committee runs the confirmation, immediately voiced “strong concerns” about her lack of managerial experience; with MDUFA VI headed to Congress in January and the agency still absorbing staff cuts, the question of who’s actually running CDRH’s parent just got a longer runway.
RAPS
2. 🤖 FDA floats “competency assessment” model for generative-AI devices
The FDA’s Digital Health Center of Excellence published a discussion paper proposing a two-axis risk framework and a premarket approach modeled on how physicians are trained and evaluated — non-clinical benchmarking plus clinical confirmation — along with risk-proportionate postmarket monitoring and first agency thinking on foundation models and agentic AI. Comments are due October 19 under docket FDA-2026-N-7874; if a large language model is anywhere in your product roadmap, the premarket path is being drawn right now and the docket is where you draw it.
FDA
3. 🧭 Most device companies don't fail on technology. They fail on sequencing.
The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you're strongest, where you're exposed, and what to fix first. If you want help closing a gap, it'll point you to the right starting place.
Sponsored by RŌG Health
4. 🧠 ARPA-H hands Siemens Healthineers $31M to build an autonomous stroke robot
Siemens Healthineers will receive up to $31.1 million over five years — plus a $5.4 million cost share of its own — to develop endovascular robotics that perform mechanical thrombectomy remotely and without direct human input, with Stryker signed on as sub-awardee under the two companies’ 2025 neurovascular partnership. The agency’s math is the story: only about 12% of 335,000 eligible U.S. stroke patients get thrombectomy each year, and more than half the population lives over an hour from a center that can do it. Autonomy isn’t the goal; distribution is.
Radiology Business
5. ⚖️ Applied Medical asks court to permanently restrict Medtronic’s hospital contracts
Six months after a federal jury hit Medtronic with $382 million in damages for bundling LigaSure below cost and locking Applied’s Voyant out of GPO contracts, Applied has moved for a permanent injunction that would bar Medtronic from penalizing hospitals — through pricing, rebates or contract terms — for buying or even trialing a competitor’s vessel sealer. Applied says it turned down a Medtronic offer to carve out Applied alone; if the court agrees the remedy should open the market rather than protect one supplier, every strategic with a bundled-contract playbook has a new template to read.
MD+DI
6. 🏭 Intuitive plans 316,000-square-foot instrument plant in Malaysia
Intuitive signed a lease with Penang Development Corp. for a facility in Bandar Cassia Technology Park that will manufacture da Vinci instruments and electromechanical components starting in 2028, with 1,200 jobs targeted by 2032. The company framed it as Asia Pacific demand, which is true; it’s also a second instrument-manufacturing base for a company whose Mexicali plant has carried a lot of tariff exposure, and a signal of where the next wave of medtech capex is landing.
MassDevice
7. 💵 CMS grants add-on payment for Aidoc’s foundation-model CT triage
Aidoc’s CARE Body CT Multi-Triage — 14 cleared indications flagged from a single foundation model — will be eligible for a Medicare New Technology Add-on Payment on qualifying fee-for-service inpatient cases starting October 1, for three years. Aidoc calls it the first NTAP for a broad, multi-finding AI built on a foundation model rather than a single-condition algorithm; if that architecture is now reimbursable, the economics of building “one model, many indications” just changed for everyone behind them.
Diagnostic Imaging
8. 🔁 Haemonetics wins back CSL’s U.S. plasma business four years after losing it
Haemonetics disclosed in an SEC filing that CSL Plasma will begin transitioning some of its U.S. collection centers to the NexSys PCS platform, reversing a 2022 non-renewal that cost Haemonetics roughly an eighth of its revenue and sent CSL’s 300-plus centers to Terumo. The deal is non-exclusive with no minimums, but shares jumped about 15% and Needham sees a potential $183–223 million in annual revenue if the switch goes all the way. A reminder that a lost anchor account isn’t necessarily lost; NexSys’ Persona Plus clearance earlier this year appears to have been the reopening.
MassDevice
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.